SINGLE DOSE TOXICITY AND PET/CT IMAGING OF RADIOPHARMACEUTI-CAL GALLIUM-68 PSMA I&T IN ANIMALS

Quốc Thắng Nguyễn, Đăng Tùng Phạm, Tuấn Ngọc Hán, Nguyen Thi Kim Dung , Hồng Sơn Mai, Ngọc Hà Lê

Main Article Content

Abstract

Objective: To evaluate single dose toxicity of radiopharmaceutical 68Ga-PSMA I&T prepared on an automatic synthesis module iQS-TS (ITM, Germany) installed at the Nuclear Medicine Department, 108 Military Central Hospital, and imaging distribution of the radiopharmaceutical in animal with positron emission tomography (PET/CT) scanner. Materials and methods: 68Ga-PSMA I&T was produced at the Nuclear Medicine Department by an automatic synthesis module iQS-TS. The animals Swiss mice were then injected doses approximately 10 mCi/kg of weight, as 100 times higher as than the equivalent human dose. The NewZealand rabbits were injected with a dose for PET/CT imaging. Result: After 14 days and 24 hours of radiopharmaceutical injection with the dose of 10 mCi per kilogram of weight. The results of hematology and biochemistry tests, weight and relative organ weight measuring of the testing groups are not statistically significant when compared to the control groups injected with saline 0,9%. In addition, the results of histology and pathology of kidneys and livers from the two mice groups show no abnormality. The PET/CT images show a high uptake in kidneys, bladder, liver, spleen and salivary glands with the standardized uptake values (SUVmax) obtained from 5 to 10. Conclusion: the radiopharmaceutical 68Ga-PSMA I&T produced by the automatic synthesis module iQS-TS in the Nuclear Medicine Department at 108 Military Central Hospital had no single dose toxicity in the mice model. 68Ga-PSMA I&T PET/CT images were consistent with the biological characteristics of animals and the pharmacodynamic of the radiopharmaceutical.

Article Details

References

1. Burkett BJ, et al. A review of theranostics: Perspectives on emerging approaches and clinical advancements. Radiology: Imaging Cancer. 2023; 5(4): e220157.
2. Hennrich U and M Eder. [68Ga] Ga-PSMA-11: The first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals. 2021; 14(8):713.
3. Golan S, et al. Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: A single-arm phase 1 trial. European Urology Oncology. 2023; 6(2):151-159.
4. Fendler WP, et al. PSMA PET/CT: Joint EANM procedure guideline/ SNMMI procedure standard for prostate cancer imaging 2.0. European journal of nuclear medicine and molecular imaging. 2023; 50(5):1466-1486.
5. Valdes-Martinez A, et al. Assessment of blood pool, soft tissue, and skeletal uptake of sodium fluoride F 18 with positron emission tomography-computed tomography in four clinically normal dogs. Am J Vet Res. 2012; 73(10): 1589-1595.
6. Banerjee SR, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. Journal of Medicinal Chemistry. 2010; 53(14):5333-5341.
7. Afshar-Oromieh A, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. Journal of Nuclear Medicine. 2015; 56(11):1697-1705.
8. Van der Gaag S, et al. Pharmacological optimization of PSMA-based radioligand therapy. Biomedicines. 2022; 10(12):3020.
9. Chatalic KL, et al. Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent. Theranostics. 2016; 6(6):849.
10. Zhao G and B Ji. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP bone scintigraphy for the detection of bone metastases in patients with prostate cancer: A meta-analysis. American Journal of Roentgenology. 2022; 219(3):386-395.